Hemab Therapeutics (COAG) Stock Insights

COAG price $38.06 -0.34 -0.87%

Ticker
COAG
Price
$38.06
Change
-0.34 -0.87%
Market cap ?
$1.78B
P/E ?
-26.58
Dividend yield ?
0.00%
Beta ?
1.85
Sector
Healthcare
Industry
Biotechnology
Stocklytics score
70
Value
66
Quality
50
Growth
95

Stocklytics score rationale: value 66, quality 50, growth 95.

Financials

2025
0

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for…

Fair value

COAG fair value Not meaningful. Price $38.06.

Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.

Not meaningful

Compare COAG

Earnings

DateEPS actualEPS estimateRevenueRevenue estimate
2026-11-10—-0.51——
2026-08-11-0.80-0.73——
2026-05-21-23.98-23.25——

Dividends

Yield 0.00%. Payout ratio 0.00%. Frequency —.

Safety score 37/100 · Watch. Payout ratio is 0% of earnings. Free-cash-flow coverage is not available, so this part stays neutral. No dividend history was found. There is no dividend yield.

Ex-dateDividendRecordPaymentFrequency
No data yet.

Insider trades

DateInsiderActionSharesPriceValue
2026-09-24Walbert KeliBuy36.00K$35.721.29M
2026-09-24Walbert KeliOther0——

Institutional holders

Latest filed quarter: Q2 2026.

Institutions holding: 57. Ownership 120.78%.

HolderSharesChangeChange %Value
RA CAPITAL MANAGEMENT, L.P.7.81MNewNew286.81M
NOVO HOLDINGS A/S4.18MNewNew153.55M
FMR LLC3.70MNewNew135.82M
CAPITAL INTERNATIONAL INVESTORS3.60MNewNew132.37M
DEEP TRACK CAPITAL, LP3.60MNewNew132.30M
SIREN, L.L.C.2.09MNewNew76.65M
AVORO CAPITAL ADVISORS LLC1.93MNewNew70.71M
BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC1.65MNewNew60.60M
JPMORGAN CHASE & CO1.15MNewNew42.33M
VANGUARD CAPITAL MANAGEMENT LLC780.76KNewNew28.68M
PRICE T ROWE ASSOCIATES INC /MD/746.04KNewNew27.40M
DRIEHAUS CAPITAL MANAGEMENT LLC715.79KNewNew26.29M
ROCK SPRINGS CAPITAL MANAGEMENT LP575.43KNewNew21.14M
BELLEVUE GROUP AG550.00KNewNew20.20M
CITADEL ADVISORS LLC523.45KNewNew19.23M
BLACKROCK, INC.283.83KNewNew10.43M
DEERFIELD MANAGEMENT COMPANY, L.P.275.00KNewNew10.10M
EXODUSPOINT CAPITAL MANAGEMENT, LP218.29KNewNew8.02M
GEODE CAPITAL MANAGEMENT, LLC211.80KNewNew7.78M
BRAIDWELL LP160.00KNewNew5.88M
MARSHALL WACE, LLP154.67KNewNew5.68M
WOODLINE PARTNERS LP150.04KNewNew5.51M
AFFINITY ASSET ADVISORS, LLC138.03KNewNew5.07M
ENSIGN PEAK ADVISORS, INC115.39KNewNew4.24M
VANGUARD FIDUCIARY TRUST CO112.50KNewNew4.13M

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener

Hemab Therapeutics (COAG) Stock Insights

COAG$38.06-0.34 -0.87%

$1.78B

Market Cap

-26.58

P/E

—

Forward P/E

70

Score

Price History